Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin

International Journal of Cardiology

Volumn 195, Issue , 2015, Pages 311-322

  Franz, Marcus ^a   Doll, Fabia ^b   Grün, Katja ^a   Richter, Petra ^a   Köse, Nilay ^a   Ziffels, Barbara ^a   Schubert, Harald ^a   Figulla, Hans R ^a   Jung, Christian ^a   Gummert, Jan ^c   Renner, André ^c   Neri, Dario ^b   Berndt, Alexander ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ETH ZURICH   (Switzerland)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Antibody; Cardiac allograft rejection; Cardiac allograft vasculopathy; Cardiac remodelling; ED A domain containing fibronectin; Interleukin 10; Interstitial fibrosis; Targeted therapy

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BRAIN NATRIURETIC PEPTIDE; CD68 ANTIGEN; F8 ANTIBODY INTERLEUKIN 10 FUSION PROTEIN; FIBRONECTIN; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; F8 MONOCLONAL ANTIBODY; IL10 PROTEIN, HUMAN; INTERLEUKIN 10; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD LEVEL; CARDIAC GRAFT REJECTION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG RESPONSE; HEART WEIGHT; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SYNDROME DELINEATION; ANIMAL; BIOLOGICAL MODEL; CHRONIC DISEASE; DISEASE MODEL; DRUG MONITORING; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT REJECTION; HUMAN; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG MONITORING; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT REJECTION; HUMANS; INTERLEUKIN-10; MODELS, CARDIOVASCULAR; MOLECULAR TARGETED THERAPY; RATS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84937540562     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.144     Document Type: Article

References (41)

1. J. Stehlik, L.B. Edwards, A.Y. Kucheryavaya, C. Benden, J.D. Christie, A.I. Dipchand, and et al. The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report - 2012 J. Heart Lung Transplant. 31 2012 1052 1064
2. J. Suzuki, M. Isobe, R. Morishita, and R. Nagai Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments Circ. J. 74 2010 233 239
3. A.T. Armstrong, P.F. Binkley, P.B. Baker, P.D. Myerowitz, and C.V. Leier Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation J. Am. Coll. Cardiol. 32 1998 704 710
4. G.A. Whalley, G.D. Gamble, and R.N. Doughty The prognostic significance of restrictive diastolic filling associated with heart failure: a meta-analysis Int. J. Cardiol. 116 2007 70 77
5. J.A. Kobashigawa, B.K. Itagaki, R.R. Razi, J.K. Patel, W. Chai, M.A. Kawano, and et al. Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation Clin. Transplant. 27 2013 E679 E684
6. J.P. Costello, T. Mohanakumar, and D.S. Nath Mechanisms of chronic cardiac allograft rejection Tex. Heart Inst. J. 40 2013 395 399
7. S.L. Bowers, I. Banerjee, and T.A. Baudino The extracellular matrix: at the center of it all J. Mol. Cell. Cardiol. 48 2010 474 482
8. J.E. Schwarzbauer, and J.L. Sechler Fibronectin fibrillogenesis: a paradigm for extracellular matrix assembly Curr. Opin. Cell Biol. 11 1999 622 627
9. L. Borsi, E. Balza, B. Gaggero, G. Allemanni, and L. Zardi The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH J. Biol. Chem. 270 1995 6243 6245
10. P.L. Jones, and F.S. Jones Tenascin-C in development and disease: gene regulation and cell function Matrix Biol. 19 2000 581 596
11. U. Gabler, A. Berndt, H. Kosmehl, U. Mandel, L. Zardi, S. Muller, and et al. Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants Heart 75 1996 358 362
12. K. Imanaka-Yoshida, M. Hiroe, T. Nishikawa, S. Ishiyama, T. Shimojo, Y. Ohta, and et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction Lab. Investig. 81 2001 1015 1024
13. M. Franz, B.R. Brehm, P. Richter, K. Gruen, D. Neri, H. Kosmehl, and et al. Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies J. Mol. Histol. 41 2010 39 50
14. A. Baldinger, B.R. Brehm, P. Richter, T. Bossert, K. Gruen, K. Hekmat, and et al. Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis Histochem. Cell Biol. 135 2011 427 441
15. N. Pasche, and D. Neri Immunocytokines: a novel class of potent armed antibodies Drug Discov. Today 17 2012 583 590
16. T. List, and D. Neri Immunocytokines: a review of molecules in clinical development for cancer therapy Clin. Pharmacol. 5 2013 29 45
17. A.J. Booth, S.C. Wood, A.M. Cornett, A.A. Dreffs, G. Lu, A.F. Muro, and et al. Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis J. Pathol. 226 2012 609 618
18. M. Franz, I. Hilger, K. Grun, S. Kossatz, P. Richter, I. Petersen, and et al. Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin J. Heart Lung Transplant. 32 2013 641 650
19. M. Franz, K. Grun, P. Richter, B.R. Brehm, M. Fritzenwanger, K. Hekmat, and et al. Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A + fibronectin, alpha-smooth muscle actin and B + tenascin-C in chronic cardiac allograft rejection Histochem. Cell Biol. 134 2010 503 517
20. M. Franz, A. Berndt, K. Grun, P. Richter, H. Kosmehl, D. Neri, and et al. Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection J. Heart Lung Transplant. 30 2011 86 94
21. M. Franz, D. Neri, and A. Berndt Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies J. Pathol. 226 2012 557 561
22. K. Schwager, M. Kaspar, F. Bootz, R. Marcolongo, E. Paresce, D. Neri, and et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis Arthritis Res. Ther. 11 2009 R142
23. Z. Zuo, C. Wang, D. Carpenter, Y. Okada, E. Nicolaidou, M. Toyoda, and et al. Prolongation of allograft survival with viral IL-10 transfection in a highly histoincompatible model of rat heart allograft rejection Transplantation 71 2001 686 691
24. J. Niu, W. Yue, Y. Song, Y. Zhang, X.F. Qi, Z. Wang, and et al. Prevention of acute allograft rejection in an orthotopic liver transplant model in rats by interleukin-10 engineered mesenchymal stem cells Clin. Exp. Immunol. 176 3 2014 473 484
25. F. Doll, K. Schwager, T. Hemmerle, and D. Neri Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse Arthritis Res. Ther. 15 2013 R138
26. A. Villa, E. Trachsel, M. Kaspar, C. Schliemann, R. Sommavilla, J.N. Rybak, and et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo Int. J. Cancer J. Int. Cancer 122 2008 2405 2413
27. K. Frey, A. Zivanovic, K. Schwager, and D. Neri Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation Integr. Biol. (Camb.) 3 2011 468 478
28. N. Pasche, J. Woytschak, S. Wulhfard, A. Villa, K. Frey, and D. Neri Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7 J. Biotechnol. 154 2011 84 92
29. K. Ono, and E.S. Lindsey Improved technique of heart transplantation in rats J. Thorac. Cardiovasc. Surg. 57 1969 225 229
30. H. Yokoyama, M. Ohmi, S. Murata, T. Nakame, K. Tabayashi, and H. Mohri Proposal of a working left heart model with a heterotopic transplantation technique in rats J. Heart Lung Transplant. 14 1995 706 712
31. V. Lange, A. Renner, M. Sagstetter, H. Harms, and O. Elert Cardiac allograft vasculopathy after cardiac transplantation and hormone therapy: positive effects? Transplantation 82 2006 234 240
32. G. Casi, and D. Neri Antibody-drug conjugates: basic concepts, examples and future perspectives J. Control. Release 161 2012 422 428
33. T. Hemmerle, and D. Neri The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer Int. J. Cancer 134 2014 467 477
34. T. Xu, C. Haering, C.K. Lau, A. Obed, J. Ma, A. Doenecke, and et al. Targeting of interleukin-10 is superior to cytotoxic T-lymphocyte associated antigen 4 with human immunoglobulin G(1) for the prevention of chronic allograft deterioration in organ transplantation J. Gene Med. 10 2008 1315 1323
35. A. Ebbs, F. Pan, C. Wynn, L. Erickson, M. Kobayashi, and H. Jiang Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration Transplant. Proc. 34 2002 1378 1381
36. H. Jiang, C. Wynn, F. Pan, A. Ebbs, L.M. Erickson, and M. Kobayashi Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production Transplantation 73 2002 1808 1817
37. C. Brandt, J. Yang, I. Schmitt-Knosalla, A. Siepert, M.H. Hammer, K. Vogt, and et al. Allo-specific T-cells encoding for viral IL-10 exert strong immunomodulatory effects in vitro but fail to prevent graft rejection Am. J. Transplant. 5 2005 268 281
38. M. Suthanthiran, and T.B. Strom Mechanisms and management of acute renal allograft rejection Surg. Clin. N. Am. 78 1998 77 94
39. M. Weis, and W. von Scheidt Cardiac allograft vasculopathy: a review Circulation 96 1997 2069 2077
40. M. Pedretti, Z. Rancic, A. Soltermann, B.A. Herzog, C. Schliemann, M. Lachat, and et al. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies Atherosclerosis 208 2010 382 389
41. M. Fiechter, K. Frey, T. Fugmann, P.A. Kaufmann, and D. Neri Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies Atherosclerosis 214 2011 325 330